RECEIVED
CENTRAL FAX CENTER
SEP 09 2008

PTOL-413A (10-07)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Applicant Initiated Interview Request Form

Application No.: 10/663,258-Conf. #2875 First Named Applicant: Jose Engelmayer
Examiner: C. M. Kam Art Unit: 1656 Status of Application: PUBLISHED

Tentative Participants:

(1) ALLEN WHITE (2) _____

(3) _____ (4) _____

Proposed Date of Interview: 09 SEPT 2008 **Proposed Time:** 2 (PM EDT)

Type of Interview Requested:

(1) [X] Telephonic (2) [ ] Personal (3) [ ] Video Conference

Exhibit To Be Shown or Demonstrated: [ ] YES [ ] NO

If yes, provide brief description: _____

Issues To Be Discussed

Issues (Rej., Obj., etc)	Claims/ Fig. #s	Prior Art	Discussed	Agreed	Not Agreed
(1) DOUBLE PATENTING REJECTION	16	U.S. PAT NO. 7323443	[ ]	[ ]	[ ]

[ ] Continuation Sheet Attached

Brief Description of Arguments to be Presented:

Double patenting rejection is moot.

An interview was conduction on the above-identified application on _____

NOTE:
This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP §713.01).
This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.

/ALLEN E. WHITE/
Applicant/Applicant's Representative Signature

Examiner/SPE Signature

ALLEN E. WHITE
Typed/Printed Name of Applicant or Representative

55727
Registration Number, if applicable

RECEIVED
CENTRAL FAX CENTER
SEP 09 2008

AMENDMENTS TO THE CLAIMS

Claims 1-14 are Canceled.

15. (Cancel)

16. (Currently amended) A method of treating a diabetic ulcer~~wound, other than ophthalmic wounds or gastric or duodenal ulcers~~, comprising the step of administering to a subject having a diabetic ulcer~~, other than by buccal administration,~~ a therapeutically effective amount of a lactoferrin composition.

17. (Original) The method of claim 16, wherein said lactoferrin composition is administered topically, orally or parenterally.

18. (Original) The method of claim 17, wherein said lactoferrin composition is administered orally.

19. (Original) The method of claim 18 further comprising administering an antacid in conjunction with said lactoferrin composition.

20. (Original) The method of claim 16 further comprising administering a standard wound healing therapy in combination with the lactoferrin composition.

21. (Original) The method of claim 16, wherein the administering comprises administering said composition for at least one week to at least twelve weeks.

22. (Original) The method of claim 16, wherein the amount of the lactoferrin that is administered is about 0.0001 μg to about 100 g per day.

23. (Original) The method of claim 16, wherein said composition is a topical gel, a solution, capsule or a tablet having a lactoferrin concentration of about 0.0001% to about 30%.

24. (Original) The method of claim 23, wherein said topical gel is composed from a polymer selected from the group of consisting of a vinyl polymer, polysaccharide

PAGE 3/5 * RCVD AT 9/9/2008 12:14:05 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/21 * DNIS:2738300 * CSID: * DURATION (mm-ss):01-30

polymer, glycosaminoglycan polymer, protein polymer, polyoxyethylene-polyoxypropylene polymer, and acrylamide polymer.

25. (Original) The method of claim 24, wherein the polymer concentration is about 0.5% (w/w) to about 3.0% (w/w) and the polymer has a molecular weight of about 50,000 to about 13,000,000.

26.-51. Canceled

52. (New) The method of claim 17, wherein said lactoferrin composition is administered topically.

53. (New) The method of claim 17, wherein said lactoferrin composition is administered parenterally.

PAGE 4/5 * RCVD AT 9/9/2008 12:14:05 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/21 * DNIS:2738300 * CSID: * DURATION (mm-ss):01-30